- Home
- OTLK vs OPFI Comparison
OTLK vs OPFI Comparison
Compare OTLK & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- OPFI
- Stock Information
- Founded
- OTLK 2010
- OPFI 2009
- Country
- OTLK United States
- OPFI United States
- Employees
- OTLK N/A
- OPFI N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- OPFI Finance: Consumer Services
- Sector
- OTLK Health Care
- OPFI Finance
- Exchange
- OTLK Nasdaq
- OPFI Nasdaq
- Market Cap
- OTLK 48.3M
- OPFI 336.3M
- IPO Year
- OTLK 2016
- OPFI N/A
- Fundamental
- Price
- OTLK $1.71
- OPFI $13.51
- Analyst Decision
- OTLK Strong Buy
- OPFI Buy
- Analyst Count
- OTLK 5
- OPFI 2
- Target Price
- OTLK $9.60
- OPFI $11.75
- AVG Volume (30 Days)
- OTLK 785.9K
- OPFI 1.4M
- Earning Date
- OTLK 08-13-2025
- OPFI 08-06-2025
- Dividend Yield
- OTLK N/A
- OPFI 7.40%
- EPS Growth
- OTLK N/A
- OPFI N/A
- EPS
- OTLK 0.83
- OPFI N/A
- Revenue
- OTLK N/A
- OPFI $305,566,000.00
- Revenue This Year
- OTLK N/A
- OPFI $112.80
- Revenue Next Year
- OTLK $379.84
- OPFI $9.34
- P/E Ratio
- OTLK $2.07
- OPFI N/A
- Revenue Growth
- OTLK N/A
- OPFI 31.46
- 52 Week Low
- OTLK $0.87
- OPFI $3.09
- 52 Week High
- OTLK $9.25
- OPFI $17.73
- Technical
- Relative Strength Index (RSI)
- OTLK 50.09
- OPFI 53.88
- Support Level
- OTLK $1.56
- OPFI $13.02
- Resistance Level
- OTLK $2.04
- OPFI $15.03
- Average True Range (ATR)
- OTLK 0.13
- OPFI 0.75
- MACD
- OTLK -0.02
- OPFI -0.05
- Stochastic Oscillator
- OTLK 31.96
- OPFI 55.69
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.